Ceftazidime and Avibactam use while Breastfeeding

Summary of Use during Lactation

Limited information indicates that ceftazidime produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Avibactam has not been studied in nursing mothers. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with cephalosporins, but these effects have not been adequately evaluated. Ceftazidime-avibactam is acceptable in nursing mothers.

Drug Levels

Maternal Levels. Ceftazidime 2 grams was given to 11 women intravenously every 8 hours for 5 days. The average trough milk level was 3.8 mg/L before the next dose, 5.2 mg/L 1 hour after the dose and 4.5 mg/L at 3 hours after the dose. These differences were not statistically significant. The average drug concentrations in milk were 3.9 mg/L for samples before the seventh dose and 4.9 mg/L in milk samples after the seventh dose, but this difference was not statistically significant. There was no correlation between the mother's weight and the ceftazidime milk levels.[1]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Blanco JD, Jorgensen JH, Castaneda YS, et al. Ceftazidime levels in human breast milk. Antimicrob Agents Chemother. 1983;23:479–80. [PMC free article: PMC184672] [PubMed: 6342531]

Substance Name

Ceftazidime and Avibactam

CAS Registry Number

1192500-31-4 78439-06-2

Drug Class

Breast Feeding

Lactation

Anti-Infective Agents

Antibacterial Agents

Cephalosporins